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ABSTRACT 
An Investigative Study into the Relationship of Bone Morphogenetic Protein 
Antagonist Expression and Osteocyte Density by Region and Quadrant 
Scott Christopher Mosher 
 
The role of cytokines and cell behavior and viability with respect to 
bone remodeling and bone behavior is an exciting area of orthopedic 
research.  The purpose of this study was to investigate the relationships 
between BMP antagonist expression and osteocyte density, lacunar densities 
and osteocyte viability in cortical bone.  Samples of unloaded tibial bone 
obtained from six C57Bl/6 mice were immunohistochemically stained for 
gremlin and noggin expression and also underwent methyl green staining to 
determine osteocyte presence.  Bone sections were divided into four 
quadrants (cranial, caudal, medial and lateral) and three regions (proximal, 
mid shaft and distal), followed by analysis across these quadrants and 
regions.  The results showed matching regional differences in gremlin 
expression with regional variations in osteocyte density, lacunar density, and 
osteocyte viability.  These variations were supported by positive correlations 
found via regression analysis.  Regression analysis also showed marginal 
negative correlations between noggin expression and osteocyte density and 
osteocyte viability, supported by regional ANOVA results.  Further research 
on loaded bone samples is needed if the relationship between these BMP 
antagonists and osteocyte densities are to be fully explained with respect to 
the bone remodeling process. 
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 1 
Introduction 
 
Bone Biology 
Physiologically, bone has three major functions.  First, and most 
obvious, it provides structure and mechanical support for muscles and 
locomotion.  Second, it provides protection for major organ systems, such as 
the cardiac and respiratory systems, as well as providing a home and 
protection for marrow. Finally, it is a storage center for many ions and 
minerals required for metabolic function, including calcium, phosphorus and a 
multitude of growth factors (Segovia-Silvestre, et al., 2009).  Many early 
studies concerning bone focused on the role of bone as a mineral reservoir 
(Martin, et al., 1998).  These studies yielded the theory that bone adaptation 
was controlled by hormones and chemical signals in the body.  It was found 
that blood calcium levels could be regulated by such signals. Parathyroid 
hormone was found to stimulate the bone cell type known as osteoclasts 
while calcitonin was found to stimulate osteoblasts, releasing calcium into the 
blood and depositing calcium in the bone respectively (Martin, et al., 1998).  
The ideas of bone adaptation have been further expanded as the years have 
progressed to include both bone modeling and remodeling. 
 Bone has both an inner and outer surface, known as the endosteum 
and periosteum respectively, the former of which is covered by a flat lining of 
cells.  The endosteum has three regions in which bone remodeling takes 
place: the trabecular, endocortical, and Haversian (Jilka, 2003). Trabecular 
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bone matter is a highly porous (75-95%) structure, connected by plates or 
struts measuring 200 microns thick, called trabeculae, in a three dimensional 
lattice (Jilka, 2003; Martin, et al., 1998).  The nonmineralized pores of 
trabecular bone provide a home for the body’s bone marrow.  Bone marrow 
itself is a tissue composed of blood vessels and nerves and is the source of 
many of the body’s stem cells- including those responsible for blood and bone 
cells (Martin, et al., 1998).  The surfaces of trabecular bone merge into the 
endocortical, which in turn merge into the Haversian canals of cortical bone 
(Jilka, 2003).  An illustration of bone structure can be found in Figure 1 below.  
Cortical bone is much less porous than trabecular bone with a porosity of only 
5-10%.  The pore space of cortical bone is made up of three space types: 1) 
the previously mentioned Haversian canals which run along the long axis of 
bone, house capillaries and nerves, and measure between 50 and 200 (see 
Bone Remodeling for further details) microns in diameter 2) the short 
transverse Haversian connecting spaces called Volksmann’s canals and 3) 
active resorption cavities (measuring near 200 microns in diameter) (Martin, 
et al., 1998).   
 3 
 
Figure 1. Bone anatomy of cortical bone (Martin, et al., 1998) 
 
The bone matrix itself is predominately composed of 5 materials: 
collagen (primarily type I), hydroxyapatite (Ca10(PO4)6(OH)2), proteoglycans, 
noncollagenous proteins, and water.  The matrix is also home to 4 major cell 
types: osteocytes, osteoblasts, osteoclasts, and bone lining cells (Martin, et 
al., 1998).  Each of these cell types performs a variety of functions within 
bone, maintaining its physiologic responsibilities.  
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Osteoblasts are the cell types responsible for bone matrix formation.  
Cuboidal in shape, osteoblasts are characterized by having large nuclei, 
extensive Golgi and endoplasmatic reticulum.  These large organelles 
indicate high levels of protein synthesis (Segovia-Silvestre, et al., 2009).  
Mature osteoblasts are rarely if ever found alone however; they seem to exist 
in small clusters consisting of a mix of active bone-forming osteoblasts and 
their bone lining cell cousins (Segovia-Silvestre, et al., 2009).  Bone formation 
begins as osteoblasts secrete type 1 collagen onto existing bone surfaces.  
This newly formed matrix is composed of unmineralized bone matrix, referred 
to as osteoid, and is laid down at a rate of about 1 micron a day (Martin, et al., 
1998; Segovia-Silvestre, et al., 2009).  Once the osteoid is formed, 
osteoblasts begin to mineralize this newly formed bone along the 
mineralization or calcification front by secreting vesicles which contain 
concentrations of calcium and phosphate in high enough levels to allow 
crystal formation, while also removing some of the water content (Manolagas, 
2000). Secretion of additional molecules required for correction matrix 
mineralization is also performed by this cell type.  These include: osteocalcin, 
osteopontin, osteonection, and bone sialoprotein (Segovia-Silvestre, et al., 
2009).  
Once their tasks are complete, osteoblasts have three potential cell 
fates.  Approximately 5% develop in bone lining cells, 25% develop into 
osteocytes, with the remaining 70% undergoing cell death via apoptosis 
(Manolagas, 2000). 
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Osteoclasts are larger than their bone forming counterparts and are 
composed of multiple nuclei (Figure 2).  Originated from hemopatoatic stem 
cells (Marks & Walker, 1981), osteoclasts differentiation requires early steps 
similar to those of monocytes and macrophages (Roodman, 2006). 
 
 
Figure 2. Osteoclast resorbing bone matrix material.  Notice the multiple 
nuclei working in concert (faculty.une.edu/com/abell/histo/osteoclast) 
 
These large cells are responsible for resorbing old or unused bone, 
releasing minerals that can be transported throughout the body (Roodman, 
1999). Resorption begins along the brush or ruffled borders of the osteoclasts 
as protons are secreted by a specific ATPase in conjunction with passive 
transport of chloride ions (Figure 3) (Martin, et al., 1998; Segovia-Silvestre, et 
al., 2009).  Catalyzation of carbon dioxide and water into H2CO3, followed by 
catalyzation into H+ and HCO3, generates these ions within the cells 
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(Segovia-Silvestre, et al., 2009). These secretions combine into hydrochloric 
acid, lowering the pH of the surrounding matrix to approximately 4.5.  The pH 
reduction then leads to dissolution of the inorganic matrix of bone.  pH 
activated cysteine proteinase cathepsin K works in conjunction with the bone-
dissolving acid  to cleave and remove the type I collagen fibers (Segovia-
Silvestre, et al., 2009).  Resorbed materials are finally removed via 
transcytosis through the osteoclasts. 
 
 
 
Figure 3. Bone resorption. The mature osteoclasts resorb bone via secretion of 
hydrochloric acid. The chloride channel ClC-7. Also required to perform resorption 
are carbonic anhydrase II (CAII), anion exchanger (AE2), αvβ3 integrin, PLEKHM1, 
OSTM1 and cathepsin K. (Segovia-Silvestre, et al., 2009) 
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As mentioned before, bone lining cells and osteocytes are relatives of 
osteoblasts.  However, while they potentially come from a common lineage, 
the two cell types possess their own responsibilities.  Osteocytes are 
osteoblasts that have become permanently differentiated and are now 
embedded in the bone matrix.  The spaces in which they reside are known as 
lacunae, of which there can be as many as 15,000 per cubic millimeter of 
bone (Martin, et al., 1998).  The lacunae are further connected by other 
tunnels in the matrix known as canaliculi (Figure 4).  These canaliculi contain 
cellular processes from neighboring osteocytes, implying communication 
between cells via chemical signals jumping across gap junctions (Martin, et 
al., 1998).   
 
Figure 4. Osteocyte lacunae (A) connected by canaliculi (B) surrounding a 
central Haversian space (C) (Martin, et al., 1998) 
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Osteocytes play many roles in bone, of which sensing mechanical 
changes, including fluid flow, substrate strain, membrane deformation, 
integrin stimulation, vibration, altered gravity, and compressive loading, may 
be the most important (Papachroni, et al., 2009).  Many believe that the 
mechanotransductive abilities of osteocytes are key to the initiation of bone 
remodeling (Papachroni, et al., 2009).  The mechanical changes are sensed 
by osteocytes in the neighboring area of bone and are then converted into 
electrical or biochemical signals.  Three coupled processes must take place 
for this to occur: mechanosensing, signal transduction and effector-cell 
response (Papachroni, et al., 2009).  When one or more of the 
mechanosenors is triggered, intracellular enzymes are activated, as well as 
secretion of growth factors that regulate local osteogenesis (Papachroni, et 
al., 2009).  These changes activate transcription factors, promoting osteoblast 
differentiation.  
Bone lining cells, our fourth and final cell type, are differentiated 
osteoblasts that remain on bone surfaces – endosteal, periosteal and 
Haversian.  They communicate with osteocytes embedded within the bone 
matrix and may play a role in mineral transfer and the sensing of mechanical 
strain. 
 
Bone Remodeling 
 The modification of bone structure and composition falls into three 
categories – osetogenesis, bone modeling and bone remodeling.  The latter 
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two can be differentiated by the interaction of bone forming and resorbing 
cells.  While bone modeling is the sculpting of a bone’s size and shape by 
independent osteoblast and osteoclast activity in separate regions of bone, 
bone remodeling requires coupled action of osteoblasts and osteoclasts to 
repair fatigue damage or change the internal architecture of bone (Martin, et 
al., 1998; Papachroni, et al., 2009).  The birth of bone remodeling research is 
commonly credited to a Julius Wolff worked published in 1892.  In this work, 
Wolff states that bones will adapt to the loads placed on them (Wolff, 1986). 
The process by which osteoclasts and osteoblasts work together to remodel 
bone has been further defined and refined over the past century. 
 Basic multicellular units (BMUs) are composed of groups of 
osteoclasts and osteoblasts working in concert, as well as osteocytes, bone 
lining cells, precursors of the bone cells and endothelial and nerve cells 
(Figure 5) (Papachroni, et al., 2009).  Coined by Harold Frost in the 1960’s, a 
BMU is often composed of hundreds of osteoblasts and tens of osteoclasts 
and usually measures near 200 microns in diameter.  Frost was the first to 
deduce that osteoblasts and osteoclasts usually work in concert while 
adapting bone rather than working separately to singularly maintain blood 
calcium levels (Martin, et al., 1998).  
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Figure 5. Longitudinal sections of Basic Multicellular Units (BMUs) stained 
via Gill’s Hematoxylin III and Eosin (H&E). BMUs were identified by the presence 
of multinucleated osteoclasts and Howship’s lacunae at the tips of their cutting cones. 
(A) Note the presence of lamellae indicating new bone formation around the closing 
cone. (B) Note the presence of several prominent nuclei in the labeled osteoclast. 
(Hadi, 2007) 
 
As bone ages and undergoes the repetitive mechanical stresses 
associated with movement, it loses some of its structural integrity.  Bone is 
B 
A 
A 
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replaced by these BMUs as the osteoclasts resorb the old or damaged bone 
and the osteoblasts lay down new bone in their wake (Jilka, 2003).  Because 
of the relatively short life span of the bone resorbing and forming cells, they 
must be continually replaced as a BMU moves through bone (Manolagas, 
2000; Papachroni, et al., 2009). By comparison, osteoclasts and osteoblasts 
typically enjoy a lifespan in a period of weeks while it has been shown that 
BMU advance in adult human bones may last for as long as 6 months, 
progressing at a rate of about 40 microns/day (Jaworski, 1992; Martin, et al., 
1998).  Interestingly, the spatial distances between cells within each unit stay 
constant for the entirety of the remodeling process. 
BMU activation is locally controlled by groups of cytokines, including 
bone morphogenetic proteins (bone growth promoters) and chemotaxins (cell 
migration regulators), as well as growth factors  (Martin, et al., 1998).  Once a 
BMU has been activated, it can take several days for the osteoclasts to form 
at the point of origin.  In cortical bone, these newly formed resorbing 
osteoclasts begin removing bone along the long axis of the bone, either 
traveling distally, proximally or both (Jilka, 2003; Martin, et al., 1998).  These 
newly formed osteoclasts reside in the cutting cone of the BMU, an area 
approximately 200 microns in diameter and 300 microns long, eventually 
creating a cavity called a resorption space.  A period of reversal in a BMU 
follows the tunneling osteoclasts before the refilling osteoblasts reach the 
cavity. This reversal period last only a few days, then the formation period of 
a BMU’s life begins.  Osteoblasts refill the resorption space by laying down 
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concentric lamellae at an average rate of 1 to 2 radial microns per day, 
slowing as the space becomes more filled (Martin, et al., 1998).  This newly 
remodeled bone, each individually referred to as an osteon, can be clearly 
identified by this radial lamellae and the line at which the new and old bone 
meet, known as the cement line (Martin, et al., 1998; Papachroni, et al., 
2009).  None of this can be done without proper vascularization of the 
working cells, so space for capillaries must be maintained.  The osteoclasts 
receive and dispose of waste via capillaries in the cutting cone, while the 
osteoblasts leave a space in the center of a forming osteon called the 
Haversian canal to provide vascularization.  As such, BMUs in cortical bone 
are sometimes referred to as Haversian BMUs. 
Because the osteoclasts primarily resorb along the long axis of the 
bone, the Haversian canals’ orientation make it possible to capture images in 
profile of BMUs along the longitudinal axis of bone as they make their way 
through the bone matrix (Jilka, 2003).  Remodeling in trabecular bone follows 
the same stages as that in cortical bone but because of the small size of 
trabeculae, a BMU must dig and refill trenches in the bone.  As such, and 
because of the complex geometry and random orientation of trabeculae, it is 
extremely hard to capture an image of a active BMU in trabecular bone (Jilka, 
2003). 
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Bone Morphogenetic Proteins and Bone Morphogenetic Protein Antagonists 
The role bone morphogenetic proteins (BMPs) play throughout the 
body has been an exciting area of research in recent years.  Members of the 
TGF-beta family of proteins, BMPs have been shown to play roles in early 
and adult neural cell development and neurogenesis, a possible regulator of 
prostate cancer, a key regulator of bone fracture healing (including initiation, 
healing speed and healing strength), as well as a role in general homeostasis 
and the development of vertebrate organs and tissues (Dean, et al., 2009; 
Haudenschild, et al., 2004; Lim, et al., 2000; Lories, et al., 2006; Rosen, 
2006; Xin, et al., 2006).  In fact, many diseases have been linked to inborn 
defects in BMP signaling, whether over or underactive (Cuny, et al., 2008). 
There are currently more than two dozen identified BMPs active and present 
in the human body, each performing a subset of activities with differing 
expression patterns (Haudenschild, et al., 2004; Wang, et al., 2006).  As far 
as their role in bone, the family of proteins originally was identified in the 
1960s by their ability to induce formation of new bone when implanted at 
ectopic subcutaneous sites in rats (Dean, et al., 2009; Haudenschild, et al., 
2004; Rosen, 2006).  They do so by recruiting progenitor stem cells and 
initiating growth and differentiation into bone through a series of events 
similar to that seen in embryogenesis (Reddi, 1998).  They also play a role in 
limb growth, possibly by triggering apoptosis in areas of developing limbs, 
sculpting them to the geometric needs (Merino, et al., 1999). 
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BMP signaling is mediated by two types of serine-threonine kinase 
receptors known as types I and II receptors (Haque, et al., 2008). BMP ligand 
must bind to a combination of two type I receptors and two type II receptors 
for signal transduction to be initiated (Figure 6). This binding induces 
phosphorylation of the type I receptor by the type II receptor (Balemans & 
Van Hul, 2002). Type I receptors then interact with a group of intracellular 
signaling factors known as Smads.  
  
Figure 6. Illustration of the signaling cascade by which bone morphogenetic 
proteins affect target cells (Balemans & Van Hul, 2002). 
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These Smads, specifically Smads-1, -5, and -8 (receptor-regulated Smads), 
undergo chemical changes and then translocate into the nucleus, where the 
completed signaling complex either interacts with various factors or binds 
directly to DNA (Balemans & Van Hul, 2002; Haque, et al., 2008).   
As with many cell signaling factors, BMPs function's can be regulated 
along any step of the signaling cascade – either extracellularly, at the cell 
membrane or intracellularly (Montero, et al., 2008).  One such regulation 
method is another family of cytokines referred to as bone morphogenetic 
protein antagonists, examples of which include noggin, gremlin, follistatin, and 
sclerostin.  BMP antagonists’ inhibitory nature, with respect to BMP function, 
stems from the binding these secreted proteins perform.  At the extracellular 
level, BMP antagonists bind to nearby BMPs, reducing their bioavailability to 
interact with type I and type II bone morphogenetic protein receptors on target 
cells (Haudenschild, et al., 2004).  Other regulatory mechanisms interact at 
the membrane and intracellular levels, such as kinase-deficient receptor 
mimics and inhibitory Smads, respectively (Haudenschild, et al., 2004).  
However, the inhibitory nature of antagonists is necessary, as studies with 
knockout mice have shown that, specifically with noggin, such mice have 
malformed limbs, stunted or improper skeletal growth, or undersized neural 
anatomy (Balemans & Van Hul, 2002; Nissim, et al., 2006).  Conversely, 
when the levels of antagonists are abnormally elevated, it has been shown 
that general mice skeletal growth becomes stunted as well as evidence 
showing deviation in limb maturation in avian models from normal skeletal 
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development (Gazzerro, et al., 2005; Merino, et al., 1999).  These studies 
indicate the need for a delicate balance between BMPs and their antagonists 
for proper overall growth. 
 As previously mentioned, bone remodeling is a series of events 
designed to allow bone to repair small amounts of damage naturally 
accumulated over time.  For the process to occur, a group of osteoclasts must 
first be initiated.  The entire process of bone remodeling after initiation to 
cavity refilling is well understood, as are the cell types involved.  What is not 
yet fully understood is the signaling pathway that informs bone cells of 
mircodamage.  However, there are several existing theories for the initiation 
of bone remodeling.   One theory suggests that the mechanosensing abilities 
of osteocytes directly influence remodeling initiation.  Another theory suggests 
variations in BMP or BMP antagonist levels.  This variation could either come 
about from mechanical changes in bone or stimulatory events.  The 
mechanical stimuli attributed with direct influence of bone remodeling have 
also been shown to be associated with changes in the homeostasis of 
hormones in the neighboring areas (Mitsui, et al., 2006).  Specifically, 
excessive compressive forces on osteoblasts induce expression of 
extracellular antagonists of BMPs, inhibiting osteoblastogenesis (Mitsui, et al., 
2006).   Another possible pathway for cell signals is associated with osteocyte 
apoptosis, whereby the dead osteocytes have either stopped releasing their 
cell signal factors or released a large amount of different factors as they 
perish.   
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The idea of local BMP variation leading to a possible mechanism for 
remodeling of bone and cartilage could be explained by either a local 
increase in the levels of BMPs or a local decrease in the levels of BMP 
antagonists.  However, this theory has not been fully researched or tested in 
either tissue.  It has been shown that noggin has inhibitory effects on BMPs-2, 
-4, -5, -6, and  -7 and is upregulated by these same BMPs as a bone 
overgrowth regulatory controller, while gremlin has inhibitory effects on 
BMPs-2, -4, and -7 (Ahn, et al., 2003; Dean, et al., 2009; Haudenschild, et al., 
2004).  In fact, it has been shown that noggin, as well as other antagonists 
including gremlin, are products of osteoblasts themselves and are produced 
as osteoblastic BMPs rise (Gazzerro, et al., 2005; Rosen, 2006).  
BMPs-2, -4 and -7 have all been shown to be potent bone inducers, so 
looking at the levels of antagonists known to inhibit these proteins may lead to 
further understanding of the interplay between them and general bone 
behavior (Nakamura, et al., 2003). This interplay has been shown to be 
extremely important, an example of which was shown in a 2003 study where 
patients feedback loop for antagonists no longer properly functioned, leading 
to skeletal muscle tissue being replaced by overactive osteoblasts with 
skeletal bone tissue (Ahn, et al.).  They have also been shown to induce the 
differentiation of osteoblast progenitors into osteoblasts, an important step in 
the remodeling process (Gazzerro, et al., 2005). 
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ELISA and Immunohistochemical Staining 
An ELISA, or Enzyme-Linked ImmunoSorbent Assay, is a technique 
used to detect an antibody or antigen in serum sample.  Antigens can be a 
variety of biologic substances, including proteins and cytokines.   
To begin an ELISA, the surface must be coated in the antigen(s) of 
interest.  This is accomplished by introducing a serum with the antigen, 
among other substances, into a series of wells.   The four major steps of an 
ELISA are shown in the figure below (Figure 7).  First, a primary antibody 
specific to the antigen of interest needs to be introduced.  The variable end of 
these antibodies bind to the antigen, leaving their constant regions exposed.  
Next, a secondary antibody with variable regions specific to the exposed 
constant regions of the primary antibody used --- for example an 
immunoglobulin G (IgG) goat specific antibody --- binds to the constant region 
of the primary antibody.  Next, this antibody is linked to an enzyme.  Again, 
the enzyme complexes change based on the type of antibody used, as well 
as the substrate being used in step four.  For the final step, an enzyme 
substrate is added to the entire antibody-enzyme complex.  Substrates emit a 
specific color, many of which fluoresce.   From this fluorescence, the amount 
of antigen can be inferred by the intensity of color emitted.  
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Figure 7. Four primary steps required to perform ELISA. 1) Primary antibody 
bonds to antigen of interest. 2) Secondary antibody, specific to primary antibody 
species and Ig super-family bonds to primary antibody. 3) Enzyme complex 
attaches/engulfs antibody groups. 4) Enzyme substrate bonds to enzyme, marking 
location and quantity of antigen. (Vectorlabs.com) 
The immunohistochemical technique used in this study is a process 
very similar to that used in classic ELISA.  The most obvious difference 
becomes apparent as the target is considered. This study will use the same 
protein chain (antibody, antibody, and enzyme) to try to indentify a cytokine in 
tissue rather than in serum.  Such a process is not uncommon and has been 
used when trying to study BMPs or BMP antagonists in bone and other 
tissues, including cartilage, neural, lung and pancreatic tissue (Haque, et al., 
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2008; Haudenschild, et al., 2004; Koli, et al., 2006; Nakamura, et al., 2003; 
Tardif, et al., 2004).  This difference should give us information on both 
location of the target cytokine and concentration, rather than just general 
concentration, as classic ELISA may be limited. 
 
Study Goals 
This study’s primary focus is testing the levels of the BMP antagonists 
noggin and gremlin as well as measure the osteocyte and lacunar densities 
by region and quadrant, and to establish the presence, if any, of BMU activity 
in unloaded murine bone.  As BMPs act as local regulators of osteoblast 
differentiation, varying levels of antagonists could have an effect on the 
activity of BMPs and therefore osteoblast activity (Balemans & Van Hul, 
2002). If levels of these antagonists are similar in regions or quadrants where 
osteocyte densities vary, we can infer that osteocyte viability has no direct 
effect on antagonist expression in unloaded environments.  However, if the 
levels vary, we can infer BMP antagonists are, at least in part, associated with 
the change in osteocyte viability and possibly by extension involved in the 
initiation or continued function of BMU remodeling.  These would be 
especially true if the levels of BMP antagonists vary by region or quadrant in a 
similar pattern as the variation in osteocyte density.  We hypothesize that the 
last scenario will be the correct one.  BMP antagonist levels will vary and this 
variation will coincide with a variation in osteocyte density.  We further 
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hypothesize that these variations could also contribute into varying levels of 
BMU activity. If true, management of BMP antagonist levels in response to 
changes in osteocyte density (by disease, fracture or other reasons) could be 
a possible treatment for bone healing.  The levels of BMP antagonists will be 
measured by the use of immunohistochemical staining in conjuncture with 
methyl green staining to help determine osteocyte and lacunar densities.  All 
these measurements will be compared between four anatomic quadrants 
(cranial, caudal, lateral and medial) as well as three regions (proximal, mid 
shaft and distal) of the right hind tibia of murine specimen.  It should be noted 
that to the best knowledge of the investigating team, no such previous study 
has taken place on cortical bone tissue, although transgenic mice who over 
express gremlin were shown to have lower bone density, higher levels of 
spontaneous bone fractures, modeling defects in long bones, and severe 
osteopenia (Gazzerro, et al., 2005). 
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Methods 
 
Research Subjects 
 Six C57 Black6 mice (C57Bl/6) were procured at 7 to 9 weeks of age 
(Taconic, Oxnard, CA), housed in microisolation chambers in the University’s 
vivarium, and later sacrificed at 8 to 12 weeks of age.  Somerville, et al.(2004) 
measured several properties indicative of skeletal maturation in C57Bl/6 mice 
including tibial length, porosity and mineral and organic mass.  They reported 
steady values in most coming between 3-4 months of age, with a full skeletal 
maturation estimate between 3-6 months though by their own admission it is 
“probably earlier in this time span rather than later”.  As such, our subjects at 
2-3 months of age sit at the border between young adulthood and full maturity 
(with respect to skeletal development). 
 
 
Perfusion Fixation 
 Each animal was anesthetized with 25% Avertin (0.15ml/10g) given via 
intraperitoneal injection and placed on a heating pad. The hair was shaved 
and limbs were taped to the heating pad. The skin was separated from the 
muscle between the abdomen and thoracic cavity. A thoracotomy was 
performed and a small incision was made in the left ventricular apex, allowing 
a vasodilator followed by histochoice to be injected; resulting in fixation of 
limbs. Once fixed, the right hind tibia were dissected and placed in 
microcentrifuge tubes with histochoice to post fix at 4 degrees Celsius. 
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 Hind limb samples were transferred into a decalcification solution to 
soften the bone prior to embedding for 3 to 4 days. The decalcification 
solution was composed of 150 grams disodium EDTA dehydrate and 15 
grams NaOH.  Water was added until the pH of the solution reached 7.4 
(between 700-800ml), yielding an approximate 15% EDTA solution.   
 
Tissue collection and Processing 
 Hind legs were collected from sacrificed murine models as per 
suggested by the University’s Institutional Animal Care and Use Committee 
(IUCAC).  Samples were fixed in Histochoice (Amresco) for a period of 
several days.  Histochoice has been shown to be a suitable substitute for the 
more classically accepted use of formaldehyde when combined with an 
alkaline phosphatase based immunohistochemical study, providing 
comparable to improved staining (Kacena, et al., 2004).  After fixation, 
samples were decalcified as stated above, after which they were placed back 
in histochoice and refrigerated until tissue processing was performed.   Tissue 
samples were cleared and embedded in paraffin using the Shandon Excelsior 
ES system (Thermo Fisher Scientific, Waltham, MA ).  Blocks were then cut 
into 6 micron thick sections, cut axially, using the Leica RM2255 rotary 
microtome (Leica Microsystems, Bannockburn, IL ).  Tissue samples were 
then floated in a warm distilled water bath (Boekel Scientific, Feasterville, PA) 
and attached to slides (Thermo Fisher Scientific) with two sections being 
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placed per slide.  Slides were allowed to dry at room temperature for 
approximately 24 hours before staining. 
 
Immunohistochemistry 
 Slides were warmed in an incubator at approximately 45-50 ºC for 10 
to 20 minutes, or until the paraffin lost its opacity.  Samples were then cleared 
of wax in a xylene bath for a period of 5 minutes and immediately rehydrated 
in a graded ethanol series (8 minutes EtOH 100%, 3 minutes 95% EtOH, 3 
minutes 80% EtOH, 3 minutes 70% EtOH, 3 minutes 50% EtOH) after which 
they were allowed to air dry for 20 minutes.  After drying, slides were washed 
for 5 minutes in a phosphate buffered saline (PBS) bath.  Slides were then 
incubated in rabbit blocking serum (Vector Laboratories, Burlingame, CA) for 
30 minutes (diluted in PBS).  After blotting of excess blocking serum, slides 
were incubated for 30 minutes in either anti-noggin goat polyclonal IgG or 
anti-gremlin goat polyclonal IgG at 200 micrograms per milliliter down to 1:50 
dilutions (diluted in PBS) (siRNA gene silencers, Santa Cruz Biotechnology, 
Santa Cruz, CA).  Slides were again washed for 5 minutes in PBS, incubated 
for 30 minutes in an Avidin/Biotinylated enzyme complex specific to goat IgG 
(Vector Laboratories)(diluted in PBS), washed again for 5 minutes in PBS, 
and incubated for 30 minutes with the VECTASTAIN® ABC-AP Reagent 
(Vector Laboratories, kit system specific for goat IgG and alkaline 
phosphatase).  The protein complex was completed with another wash in 
PBS for 5 minutes followed by 30 minute incubation in the VectaStain Red 
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substrate (Vector Laboratories), and a final 5 minute PBS wash.  Both the 
VECTASTAIN® ABC-AP Reagent and VectaStain Red substrate were 
prepared as instructed by the available company protocols. A 2% methyl 
green counterstain was performed immediately after primary staining was 
completed.  The methyl green counterstaining solution was prepared as 
follows- 2.72 grams of sodium acetate, trihydrate (MW 136.1) (Sigma, St. 
Louis, MO) was mixed into 200 ml of distilled water.  Once dissolved, the pH 
was adjusted to 4.2 using concentrated glacial acetic acid (Sigma).  Next, 4 
grams of methyl green (<0.5% crystal violet) (Sigma) were mixed into 200ml 
of the 0.1 M sodium acetate buffer until dissolved.  Samples were placed in 
methyl green for 10 minutes, followed by 10 dips in distilled water and 30 
seconds in a fresh distilled water bath.  Next, samples were dipped 10 times 
in n-butanol (Sigma) and then placed in fresh n-butanol (Sigma) for 30 
seconds.  Slides were then mounted with mounting medium (Thermo Fischer 
Scientific) and coverslipped. 
Control slides were also created following the same procedures as 
stated above, excluding the administration and incubation with either primary 
noggin antibody or primary gremlin antibody.  It should also be noted that all 
products obtained from VectorLabs were used at their suggested 
concentrations, excluding the blocking serum which was used at a higher 
concentration (double concentration) in order to ensure blocking of 
nonspecific binding.  All incubation times for VectorLabs products were also 
performed at suggested times; again excluding blocking serum incubation 
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time, which was increased from 20 to 30 minutes to ensure blocking.  Other 
procedures follow the general steps of immunohistochemical staining 
described in literature (such as those of Hedgecock, et al. (2007) and 
Haudenschild, et al. (2004)) but specifics were developed in house as 
needed. 
To facilitate the analysis, each axial section of bone was divided into 
four anatomic quadrants: cranial, caudal, medial, and lateral, the equivalent of 
anterior, posterior, medial, and lateral in a bipedal subject, respectively. 
 
Osteocyte and Lacunar Densities 
To detect the presence and number of viable osteocytes, the methyl 
green staining protocol was performed as previously stated.  Slides were then 
observed under full-spectrum white light using a BX41 polarizing light 
microscope (Olympus Optical Co., Ltd., Center Valley, PA) and a Retiga EXi 
color camera (QImaging, Surrey, BC, Canada).  The Q Capture Pro imaging 
program (QImaging) was used in conjunction with the Retiga EXi to capture 
and catalog images at both 4x magnification and 40x magnification, the 
former of which is used to capture an image of the entire bone section, the 
latter of which is used to identify osteocytes and empty lacunae.  A Ronchi 
ruler with known lines at a size of 150 lines per mm was used to calibrate 
images at the 40x magnification.  Image analysis was performed using 
ImageJ (Wayne Rasband (NIH)) where images were calibrated according to 
the above Ronchi ruler, yielding total field dimensions of 0.23mm by 0.17mm.  
 27 
From there bone area was measured using the freehand selection tool, giving 
the area of interest in square millimeters (Figure 8).  Positively stained 
osteocytes were identified when they were: 1) positively stained for the methyl 
green staining agent and 2) resided within a lacuna with a clearly defined 
border (Figure 9).  It was necessary to only include those cells stained that 
resided within lacunae to eliminate cells residing in Haversian spaces or 
those that accidently migrated over bone tissue during the staining procedure.  
Osteocyte density was then measured both within each of the four quadrants, 
three regions, as well as the total osteocyte density per subject by dividing the 
number of positively stained osteocytes by the bone area measured, yielding 
osteocyte density in number of osteocytes per square millimeter.  
Total lacunar density was measured in a similar way.  All lacunae 
observed to contain positively stained osteocytes were counted towards the 
number of total lacunae in addition to any lacunae with clearly defined 
boarders not containing positively stained osteocytes.  Calculations were then 
done in the same manner as osteocyte density for the four quadrants, three 
regions, as well as total density per subject. 
Finally, the percentage of lacunae containing viable osteocytes was 
calculated as the total number of positively stained osteocytes divided by the 
total number of lacunae for each of the four quadrants, each of the three 
regions, as well as for each subject. 
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Figure 8. Example of ImageJ measurement of bone area. Note A) freehand 
tool used to outline bone B) bone area displayed C) complete bone area in image field 
outlined to keep consistent measurements (boarding yellow line) 
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Figure 9. Example of A) positively stained osteocytes residing in lacunae B) 
negatively stained (empty) lacunae C) non-specifically stained cells (not in lacunae), 
not counted toward positive osteocyte count 
   
Noggin and Gremlin detection 
 To detect the presence and levels of noggin and gremlin in bone, the 
immunohistochemical staining protocol was performed as previously stated.  
Slides were then observed under full-spectrum white light using a BX41 
polarizing light microscope (Olympus Optical Co., Ltd., Center Valley, PA) 
and a Retiga EXi color camera (QImaging, Surrey, BC, Canada).  The Q 
Capture Pro imaging program (QImaging) was used in conjunction with the 
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Retiga EXi to capture and catalog images at both 4x magnification and 40x 
magnification, the former of which is used to capture an image of the entire 
bone section.  ImageJ (Wayne Rasband (NIH)) was used to observe general 
levels of BMP antagonist present in each 40x magnification image, 
quantification of which is described in a later section below. 
 
BMU Identification 
 BMUs can be visually identified by their distinct shape within the bone 
matrix.  From an axial view point, these identifying features include the 
comparatively large cavity space left in the osteon as well as the concentric 
lamellae recently laid down by the osteoblasts.  For some active BMUs, we 
were also able to see the stained nuclei of bundled groups of 
osteoclasts/osteoblasts but without staining specific for the time period of 
BMU life span (such as tetracycline double staining), we were unable to 
identify the time period.  For others, we were able to see a clearly defined 
cement wall with newly formed bone residing within cortical bone (Figure 10).  
Another example of a BMU, this one in the process of refilling, can be seen in 
Figure 11.  
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Figure 10. Newly formed osteon residing within hind murine limb. Note the 
presence of distinct cement line (denote by arrow) bordering newly formed bone. 
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Figure 11. Axial section of a refilling Haversian Basic Multicellular Unit 
(BMU) found in murine hind tibia.  Tissue is unaltered and viewed under white light.  
Note lamellar bone matrix being refilled by osteoblasts in a radial manner. 
Noggin and Gremlin Quantification 
 Quantification of both BMP antagonists followed similar procedures of 
those used by Nakamura, et al., (2003) who quantified BMP receptors and 
noggin in vertebral samples.  Nakamura’s group classified the levels of their 
immunohistochemical staining into five levels: not detectable, trace, weak, 
moderate, and strong.  This study uses the same level system, examples of 
which can be seen in Figure 12.  After initial ratings were assigned to 
individual 40x magnification images, each rating was attributed a numeric 
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value; zero for not detectable, one for trace, two for weak, three for moderate 
and four for strong.  The numeric values allowed for the average staining level 
(as a numeric value) to be determined for each of the four quadrants and 
three regions of bone within and between subjects. 
 
Figure 12. Examples of images 
depicting the five levels of 
immunohistochemical staining. From left 
to right, top to bottom examples show: not 
detectable, trace staining, weak staining, 
moderate staining, and strong staining. 
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Statistical Methods 
 To find differences in osteocyte density, total lacunar density, 
percentage of lacunae containing viable osteocytes, and the level of BMP 
antagonists, data was tested using general linear models (GLM, ANOVA) 
provided in the statistical analysis program Minitab 15 (Minitab).   Initially, 
GLM were performed testing differences with the interaction between the 
factors of region and quadrant across all subjects.  If the interactional factor 
was not deemed to be significant (P >.05), region and quadrant were tested 
individually across all subjects.  If either factor was individually found to have 
significance, post-hoc analysis was performed by Tukey’s comparison. 
 P values less than .05 were deemed significant, while p values less 
than .15 were deemed to be marginally significant.  Residuals for all tests 
were plotted to determine normality of the data. 
 Additionally, regression analyses were performed comparing BMP 
antagonist expression level vs. osteocyte density, lacunar density and the 
percentage of lacunae containing viable osteocytes at each of the twelve 
region/quadrant combinations. 
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Results 
 
Osteocyte and Lacunar Densities 
Table 1 below summarizes the findings for osteocyte density (OD), 
total lacunar density (TLD), and the percentage of lacunae containing viable 
osteocytes (%OD/TLD). To verify the validity of the study, the total OD across 
all subjects was compared to previous studies measuring osteocyte densities.  
Bucay, et al. (1998) reported osteocyte densities between 750 and 800 per 
mm2 in tibial mouse diaphysis with the use of H & E staining.  Erlebacher, et 
al. (1996; 1998) reported similar numbers, approximately 700 osteocytes per 
mm2, in the cortical bone from the femoral diaphysis at the level of the third 
trochanter where periosteal bone resorption was absent, also with the use of 
H & E staining. Mullender, et al. (1996) reported slightly higher number in rat 
femur at 942.8 mm2; however, species and location could both factor into this 
slightly raised value.  Our measurements yielded an OD of 676 with a 
standard deviation of 80.8.  Comparing this result to the studies mentioned 
above, our OD was significantly lower than the rat model (p <0.01; two 
sample t-test) but was similar to that found in the study by Erlebacher, et al. 
(p >0.60; two sample t-test). 
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Table 3. Osteocyte densities, total lacunar densities, and the percentage of 
lacunae containing viable osteocytes by individual subjects. Standard deviations in 
paren. 
Subject  Osteocyte 
Density 
(mm2) 
Total 
Lacunar 
Density 
(mm2) 
% Lacunae 
Viable 
osteocyte 
N (Sample 
number) 
40  595 838 71.0 94 
42 724 922 78.5  439 
44 625 848 73.6  151 
88 650 862 75.4 100 
90 816 1009 80.8 118 
93 646 801 80.7 400 
Overall 676(80.8) 880(74.5) 76.7(4.00) 1303 
 
Results for differences in OD, TLD, and %OD/TLD across all subjects 
with respect to the interaction between quadrant and region can be seen in 
appendix A.  Since no terms were found to be significantly different for any of 
the three values of interest, differences were tested across all subjects by 
region and quadrant independently.  Mean values and standard deviations for 
quadrantal data across subjects (Tables 2 and 2a-2c) were calculated from 
aggregate quadrantal data from all six subjects (Tables 3 through 8).  Sub-
tables (Tables 2a-2c and 9a-9d) were used in the regression analysis. 
Analysis, as seen in Tables 2 and 2a-2c, shows no differences in OD, 
TLD, nor %OD/TLD when compared across quadrants, although a marginally 
significant difference was detected in TLD between the medial and lateral 
quadrants in the proximal region.   
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Table 4. Quadrantal differences of osteocyte density (OD), total lacunar 
density (TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) 
across all subjects. Standard deviations in parentheses. 
Quadrant OD/mm2 TLD/mm2 % OD/TLD 
Cranial (Cr) 691(94.5) 891(82.4) 77.4(5.72) 
Caudal (Cd) 659(87.7) 877(94.0) 75.2(6.45) 
Medial (M) 648(136) 833(128) 77.4(4.93) 
Lateral (L) 700(44.0) 932(49.9) 75.3(5.21) 
Cr-Cd .9372 .9942 .8978 
Cr-M .8691 .7106 1.000 
Cr-L .9984 .8724 .9093 
Cd-M .9976 .8446 .9055 
Cd-L .8793 .7461 1.000 
M-L .7907 .2898 .9166 
 
 
Table 2a. Mean quandrantal data for osteocyte density (OD), total lacunar 
density (TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) 
across all subjects, data gathered from proximal region only.  Standard deviations in 
parentheses. 
 
Quadrant OD/mm2 TLD/mm2 % OD/TLD 
Cranial (Cr) 676(22) 841(33.3) 80.5(.562) 
Caudal (Cd) 562(28.2) 813(32.4) 69.9(11.1) 
Medial (M) 594(133) 775(141) 76.2(3.93) 
Lateral (L) 736(128) 997(183) 74.0(5.89) 
Cr-Cd .5491 .9945 .4286 
Cr-M .5364 .7686 .9315 
Cr-L .8883 .5534 .7563 
Cd-M 1.000 .8449 .6761 
Cd-L .1779 .3468 .8696 
M-L .1719 .1235 .9669 
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Table 2b. Mean quandrantal data for osteocyte density (OD), total lacunar 
density (TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) 
across all subjects, data gathered from midshaft region only.  Standard deviations in 
parentheses. 
 
Quadrant OD/mm2 TLD/mm2 % OD/TLD 
Cranial (Cr) 797(65.1) 985(62.1) 80.9(1.50) 
Caudal (Cd) 743(31.4) 957(36.2) 77.7(.349) 
Medial (M) 779(172) 965(138) 80.3(6.30) 
Lateral (L) 727(34.6) 924(39.2) 78.7(.401) 
Cr-Cd .9381 .9839 .7682 
Cr-M .9973 .9940 .9975 
Cr-L .8767 .8661 .9050 
Cd-M .9796 .9996 .8523 
Cd-L .9977 .9719 .9876 
M-L .9412 .9499 .9588 
 
 
 
Table 2c. Mean quandrantal data for osteocyte density (OD), total lacunar 
density (TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) 
across all subjects, data gathered from distal region only. Standard deviations in 
parentheses. 
 
Quadrant OD/mm2 TLD/mm2 % OD/TLD 
Cranial (Cr) 616(31.5) 874(62.0) 70.5(4.83) 
Caudal (Cd) 607(129) 799(153) 75.9(1.92) 
Medial (M) 632(83.0) 858(90.8) 73.6(4.20) 
Lateral (L) 636(119) 852(211) 75.6(6.66) 
Cr-Cd .9995 .9071 .5448 
Cr-M .9973 .9987 .8604 
Cr-L .9943 .9967 .5754 
Cd-M .9900 .9534 .9306 
Cd-L .9837 .9656 .9999 
M-L .9999 1.000 .9467 
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Table 3. Aggregate data for osteocyte density (OD), total lacunar density 
(TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) for 
subject 40.  
Quadrant OD/mm2 TLD/mm2 % OD/TLD 
Cranial (Cr) 584 878 66.5 
Caudal (Cd) 602 848 71.0 
Medial (M) 501 711 70.4 
Lateral (L) 732 963 76.1 
 
Table 4. Aggregate data for osteocyte density (OD), total lacunar density 
(TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) for 
subject 42.  
 
Quadrant OD/mm2 TLD/mm2 % OD/TLD 
Cranial (Cr) 751 941 79.8 
Caudal (Cd) 721 932 77.4  
Medial (M) 658 868 75.8 
Lateral (L) 702  896 78.4  
 
 
Table 5. Aggregate data for osteocyte density (OD), total lacunar density 
(TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) for 
subject 44.  
Quadrant OD/mm2 TLD/mm2 % OD/TLD 
Cranial (Cr) 661 817 80.9 
Caudal (Cd) 554 862 64.3 
Medial (M) 648 849 76.4 
Lateral (L) 623 902 69.0 
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Table 6. Aggregate data for osteocyte density (OD), total lacunar density 
(TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) for 
subject 88.  
 
Quadrant OD/mm2 TLD/mm2 % OD/TLD 
Cranial (Cr) 616  812 75.9 
Caudal (Cd) 721 925 78.0 
Medial (M) 587 774 75.8 
Lateral (L) 689  1005 68.6 
 
Table 7. Aggregate data for osteocyte density (OD), total lacunar density 
(TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) for 
subject 90.  
 
Quadrant OD/mm2 TLD/mm2 % OD/TLD 
Cranial (Cr) 843 1029 81.9 
Caudal (Cd) 766 983 77.9 
Medial (M) 901 1063 84.7  
Lateral (L) 751 951 79.0 
 
 
 
 
Table 8. Differences in osteocyte density (OD), total lacunar density (TLD), 
the percentage of lacunae containing viable osteocytes (%OD/TLD) between 
quadrants for subject 93.  
 
Quadrant OD/mm2 TLD/mm2 % OD/TLD 
Cranial (Cr) 690 868 79.5 
Caudal (Cd) 588 714 82.4 
Medial (M) 595 735 81.0  
Lateral (L) 702  872 80.5 
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Unlike the comparisons made across quadrants, differences became 
apparent when compared between regions across subject (Tables 9 and 9a-
9d).  Table 9 below shows differences in OD and TLD between the mid shaft 
and proximal regions, both of which showed higher average values in the mid 
shaft region.  OD was also significantly higher in the mid shaft region as 
compared to the distal region, with near marginal differences in TLD between 
the two regions.  The distal region also showed significantly lower 
percentages of lacunae containing viable osteocytes compared to both the 
proximal and mid shaft regions. 
 
Table 9. Regional differences of osteocyte density (OD), total lacunar density 
(TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) across all 
subjects.  Standard deviations in parentheses. 
Region OD/mm2 TLD/mm2 % OD/TLD 
Proximal (P) 631(52.8) 808(74.2) 78.3(2.12) 
Mid Shaft (MS) 730(27.1) 928(26.0) 78.6 (1.08) 
Distal (D) 627(23.6) 858(32.9) 73.9(2.23) 
P-MS .0111 .0176 .9725 
P-D .9819 .3637 .0232 
MS-D .0085 .1614 .0164 
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Table 9a. Mean regional data for osteocyte density (OD), total lacunar density 
(TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) across all 
subjects, data gathered from cranial quadrant only. Standard deviations in 
parentheses. 
Region OD/mm2 TLD/mm2 % OD/TLD 
Proximal (P) 676(22) 841(33.3) 80.5(.562) 
Mid Shaft (MS) 797(65.1) 985(62.1) 80.9(1.50) 
Distal (D) 616(31.5) 874(62.0) 70.5(4.83) 
P-MS .0880 .1276 .9931 
P-D .3404 .7876 .0764 
MS-D .0183 .1979 .0682 
 
 
 
Table 5. Mean regional data for osteocyte density (OD), total lacunar density 
(TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) across all 
subjects, data gathered from caudal quadrant only. Standard deviations in 
parentheses. 
Region OD/mm2 TLD/mm2 % OD/TLD 
Proximal (P) 562(28.2) 813(32.4) 69.9(11.1) 
Mid Shaft (MS) 743(31.4) 957(36.2) 77.7(.349) 
Distal (D) 607(129) 799(153) 75.9(1.92) 
P-MS .1339 .3980 .5087 
P-D .8006 .9861 .5986 
MS-D .2748 .3402 .9586 
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Table 9c. Mean regional data for osteocyte density (OD), total lacunar density 
(TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) across all 
subjects, data gathered from medial quadrant only. Standard deviations in 
parentheses. 
Region OD/mm2 TLD/mm2 % OD/TLD 
Proximal (P) 594(133) 775(141) 76.2(3.93) 
Mid Shaft (MS) 779(172) 965(138) 80.3(6.30) 
Distal (D) 632(83.0) 858(90.8) 73.6(4.20) 
P-MS .1867 .1742 .7005 
P-D .7419 .4104 .7330 
MS-D .4039 .5389 .3558 
 
 
Table 9d. Mean regional data for osteocyte density (OD), total lacunar density 
(TLD), the percentage of lacunae containing viable osteocytes (%OD/TLD) across all 
subjects, data gathered from lateral quadrant only. Standard deviations in parentheses. 
Region OD/mm2 TLD/mm2 % OD/TLD 
Proximal (P) 736(128) 997(183) 74.0(5.89) 
Mid Shaft (MS) 727(34.6) 924(39.2) 78.7(.401) 
Distal (D) 636(119) 852(211) 75.6(6.66) 
P-MS .9961 .8949 .6518 
P-D .5580 .6064 .9301 
MS-D .6674 .8994 .8292 
 
 
 
BMP Antagonist levels 
Results for differences in the level of individual expression of noggin 
and gremlin are reported here independent of one another across all subjects 
with respect to the interaction between quadrant and region. As the BMP 
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antagonist control subject, the data for subject 40 was omitted.  Since no p 
values for any of the interactive factor terms were found to be significantly 
different for BMP antagonist levels, differences were tested across all 
subjects by region and quadrant independently.  Regional and quandrantal 
analysis was performed and can be seen in tables 10, 11, 12 and 13.  Noggin 
showed differences both quadrantally and regionally (Tables 10 and 11).  
Noggin expression was higher in the cranial region as compared to the 
caudal, as well higher proximally compared to distally and proximally 
compared to mid shaft.  Furthermore, noggin in the distal region showed 
marginally significantly higher expression compared to mid shaft expression.  
Gremlin also showed differences between regions with mid shaft showing 
higher expression than the distal region as well as the proximal region, while 
no differences in gremlin levels were significant when compared between 
quadrants (Tables 12 and 13). Again, sub-tables (Tables 10a-10c, 11a-11d, 
12a-12c, and 13a-13d) were used in the regression analysis.  Tables 14-18 
show average BMP antagonist expression for individual subject, with results 
for subject 42 and 93 split by noggin and gremlin results. 
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Table 10. Quadrantal differences in average level of noggin expression 
between quadrants across all subjects. Standard deviations in parentheses. 
Quadrant BMPA level 
Cranial (Cr) 2.07(.859) 
Caudal (Cd) 2.27(.878) 
Medial (M) 2.16(.896) 
Lateral (L) 2.17(.883) 
Cr-Cd .0411 
Cr-M .9903 
Cr-L .7458 
Cd-M .2956 
Cd-L .7091 
M-L .9326 
 
Table 6a. Average level of noggin expression between quadrants across all 
subjects, data gathered from proximal region only.  Standard deviations in 
parentheses. 
 
Quadrant BMPA level 
Cranial (Cr) 2.33(.844) 
Caudal (Cd) 2.63(.830) 
Medial (M) 2.49(.978) 
Lateral (L) 2.55(.959) 
Cr-Cd .0685 
Cr-M .7535 
Cr-L .4712 
Cd-M .7787 
Cd-L .9546 
M-L .9819 
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Table 70b. Average level of noggin expression between quadrants across all 
subjects, data gathered from mid shaft region only.  Standard deviations in 
parentheses. 
 
Quadrant BMPA level 
Cranial (Cr) 1.75(.666) 
Caudal (Cd) 2.00(.721) 
Medial (M) 2.06(.814) 
Lateral (L) 1.80(.661) 
Cr-Cd .3820 
Cr-M .0898 
Cr-L .9035 
Cd-M .8723 
Cd-L .9441 
M-L .6447 
 
 
Table 8c. Average level of noggin expression between quadrants across all 
subjects, data gathered from distal region only.   Standard deviations in parentheses. 
 
Quadrant BMPA level 
Cranial (Cr) 2.35(1.10) 
Caudal (Cd) 1.96(1.04) 
Medial (M) 1.76(.663) 
Lateral (L) 2.14(.949) 
Cr-Cd .0673 
Cr-M .0983 
Cr-L .9761 
Cd-M .9764 
Cd-L .4696 
M-L .6447 
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Table 91. Regional differences in average level of noggin expression between 
regions across all subjects.   Standard deviations in parentheses. 
Region BMPA level 
Proximal (P) 2.48(.887) 
Mid Shaft (MS) 2.17(.883) 
Distal (D) 2.08(.992) 
P-MS .0000 
P-D .0496 
MS-D .0620 
 
 
Table 11a. Average level of noggin expression between regions across all 
subjects, data gathered from cranial quadrant only.   Standard deviations in 
parentheses. 
 
Region BMPA level 
Proximal (P) 2.33(.844) 
Mid Shaft (MS) 1.75(.666) 
Distal (D) 2.35(1.10) 
P-MS .0000 
P-D .9873 
MS-D .0002 
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Table 101b. Average level of noggin expression between regions across all 
subjects, data gathered from caudal quadrant only.   Standard deviations in 
parentheses. 
 
Region BMPA level 
Proximal (P) 2.63(.830) 
Mid Shaft (MS) 2.00(.721) 
Distal (D) 1.96(1.04) 
P-MS .0000 
P-D .0010 
MS-D .9792 
 
Table 111c. Average level of noggin expression between regions across all 
subjects, data gathered from medial quadrant only.   Standard deviations in 
parentheses. 
 
Region BMPA level 
Proximal (P) 2.49(.978) 
Mid Shaft (MS) 2.06(.814) 
Distal (D) 1.76(.663) 
P-MS .0822 
P-D .0032 
MS-D .3828 
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Table 121d. Aaverage level of noggin expression between regions across all 
subjects, data gathered from lateral quadrant only.   Standard deviations in 
parentheses. 
Region BMPA level 
Proximal (P) 2.55(.959) 
Mid Shaft (MS) 1.80(.661) 
Distal (D) 2.14(.949) 
P-MS .0003 
P-D .2523 
MS-D .3826 
 
 
 
Table 132. Quadrantal differences in average level of gremlin expression 
between quadrants across all subjects.  Standard deviations in parentheses. 
Quadrant BMPA level 
Cranial (Cr) 1.79(.810) 
Caudal (Cd) 1.74(.849) 
Medial (M) 1.63(.760) 
Lateral (L) 1.66(.799) 
Cr-Cd .4899 
Cr-M .6369 
Cr-L .5127 
Cd-M .9993 
Cd-L .9923 
M-L .9992 
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Table 142a. Average level of gremlin expression between quadrants across all 
subjects, data gathered from proximal region only.   Standard deviations in 
parentheses. 
 
Quadrant BMPA level 
Cranial (Cr) 1.59(.834) 
Caudal (Cd) 1.47(.728) 
Medial (M) 1.47(.725) 
Lateral (L) 1.38(.682) 
Cr-Cd .7265 
Cr-M .8424 
Cr-L .4525 
Cd-M 1.000 
Cd-L .9397 
M-L .9509 
 
Table 152b. Average level of gremlin expression between quadrants across all 
subjects, data gathered from mid shaft region only.   Standard deviations in 
parentheses. 
 
Quadrant BMPA level 
Cranial (Cr) 2.02(.729) 
Caudal (Cd) 1.98(.878) 
Medial (M) 1.87(.763) 
Lateral (L) 1.97(.822) 
Cr-Cd .8497 
Cr-M .4896 
Cr-L .7487 
Cd-M .4576 
Cd-L .8502 
M-L .2399 
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Table 12c. Average level of gremlin expression between quadrants across all 
subjects, data gathered from distal region only.   Standard deviations in parentheses. 
 
Quadrant BMPA level 
Cranial (Cr) 1.00(.000) 
Caudal (Cd) 1.00(.000) 
Medial (M) 1.00(.000) 
Lateral (L) 1.5(.707) 
Cr-Cd 1.000 
Cr-M 1.000 
Cr-L .1564 
Cd-M 1.000 
Cd-L .2053 
M-L .2641 
 
Table 13. Regional differences in average level of gremlin expression between 
regions across all subjects. Standard deviations in parentheses. 
Region BMPA level 
Proximal (P) 1.52(.773) 
Mid Shaft (MS) 1.66(.799) 
Distal (D) 1.08(.289) 
P-MS .0000 
P-D .2708 
MS-D .0003 
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Table 163a. Average level of gremlin expression between regions across all 
subjects, data gathered from cranial quadrant only.   Standard deviations in 
parentheses. 
Region BMPA level 
Proximal (P) 1.59(.834) 
Mid Shaft (MS) 2.02(.729) 
Distal (D) 1.00(.000) 
P-MS .0000 
P-D .2161 
MS-D .0107 
 
Table 1173b. Average level of gremlin expression between regions across all 
subjects, data gathered from caudal quadrant only.   Standard deviations in 
parentheses. 
Region BMPA level 
Proximal (P) 1.47(.728) 
Mid Shaft (MS) 1.98(.878) 
Distal (D) 1.00(.000) 
P-MS .0006 
P-D .5891 
MS-D .1037 
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Table 13c. Average level of gremlin expression between regions across all 
subjects, data gathered from medial quadrant only.   Standard deviations in 
parentheses. 
Region BMPA level 
Proximal (P) 1.47(.725) 
Mid Shaft (MS) 1.87(.763) 
Distal (D) 1.00(.000) 
P-MS .0739 
P-D .6512 
MS-D .2445 
 
Table 183d. Average level of gremlin expression between regions across all 
subjects, data gathered from lateral quadrant only.   Standard deviations in 
parentheses. 
Region BMPA level 
Proximal (P) 1.38(.682) 
Mid Shaft (MS) 1.97(.822) 
Distal (D) 1.5(.707) 
P-MS .0038 
P-D .9730 
MS-D .6659 
 
Table 194a. Average noggin expression (BMPA level) between quadrants for 
subject 42. Standard deviations in parentheses. 
Quadrant BMPA level 
Cranial (Cr) 1.75 (.666) 
Caudal (Cd) 2.01(.726) 
Medial (M) 2.06(.814) 
Lateral (L) 1.80(.601) 
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Table 204b. Average gremlin expression (BMPA level) between quadrants for 
subject 42. Standard deviations in parentheses. 
Quadrant BMPA level 
Cranial (Cr) 1.90(.690) 
Caudal (Cd) 1.80(.885) 
Medial (M) 1.69(.704) 
Lateral (L) 1.95(.911) 
 
 
Table 15. Average bone morphogenetic protein antagonist expression (BMPA 
level) between quadrants for subject 44. Standard deviations in parentheses. Note: 
Stained for noggin only. 
Quadrant BMPA level 
Cranial (Cr) 1.89(.819) 
Caudal (Cd) 2.18(.914)  
Medial (M) 1.63(.770) 
Lateral (L) 1.88(.900)  
 
Table 16. Average bone morphogenetic protein antagonist expression (BMPA 
level) between quadrants for subject 88. Standard deviations in parentheses. Note: 
Stained for noggin only. 
Quadrant BMPA level 
Cranial (Cr) 2.35(1.14) 
Caudal (Cd) 1.96(1.08)  
Medial (M) 1.74(.689)  
Lateral (L) 2.14(.949)  
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Table 21. Average bone morphogenetic protein antagonist expression (BMPA 
level) between quadrants for subject 90. Standard deviations in parentheses. Note: 
Stained for gremlin only. 
Quadrant BMPA level 
Cranial (Cr) 2.19(.754) 
Caudal (Cd) 2.30(.684)  
Medial (M) 2.06(.799)  
Lateral (L) 2.00(.730)  
 
 
 
 
Table 18a. Average noggin (BMPA level) between quadrants for subject 93. 
Standard deviations in parentheses. 
Quadrant BMPA level 
Cranial (Cr) 2.38(.860) 
Caudal (Cd) 2.65(.726) 
Medial (M) 2.69(.931) 
Lateral (L) 2.81(.786) 
 
Table 228b. Average gremlin (BMPA level) between quadrants for subject 93. 
Standard deviations in parentheses. 
Quadrant BMPA level 
Cranial (Cr) 1.62(.907) 
Caudal (Cd) 1.41(.660) 
Medial (M) 1.44(.700) 
Lateral (L) 1.25(.645) 
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Regression Analysis 
 Linear regression analysis of noggin expression versus OD and the 
%OD/TLD both show marginally significant negative correlation in expression 
associated with increases in density and viablility (R2 = .2159 and .264) (Table 
19, Figures 13 and 15).  While a negative correlation was also found between 
noggin expression and TLD, the relationship was not deemed to be significant 
(Table 19).  Interestingly, the relationships between gremlin expression and 
OD, TLD and %OD/TLD all showed positive correlations (significant with 
respect to OD and %OD/TLD and marginally significant with respect to TLD) 
as opposed to the decreases seen in noggin expression (R2 =.5348, .3246 
and .4961) (Table 19, Figures 13-15). 
 
Table 23. Linearly relationships between BMP antagonist expression and OD, 
TLD and %OD/TLD. 
Noggin Expression vs. OD TLD %OD/TLD 
Slope -.0019 -.0013 -.0436 
R
2
 .2159 .0965 .264 
P value 0.13 0.33 0.087 
 
Gremlin Expression vs. OD TLD %OD/TLD 
Slope .0036 .0029 .0733 
R
2
 .5348 .3246 .4961 
P value 0.007 0.053 0.01 
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Figure 13. Regression analysis of BMP expression vs. osteocyte density.  Data 
from proximal region represented with the symbol ♦ (diamond), mid shaft region 
represent with the symbol ● (circle), distal region represented with the symbol 
▲(triangle).  Cranial, caudal, medial and lateral points are color as blue, red, green 
and gold, respectively.  All points indicating noggin levels are solid, while all points 
indicating gremlin levels are shape outlines only. 
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Figure 14. Regression analysis of BMP expression vs. osteocyte density.  Data 
from proximal region represented with the symbol ♦ (diamond), mid shaft region 
represent with the symbol ● (circle), distal region represented with the symbol 
▲(triangle).  Cranial, caudal, medial and lateral points are color as blue, red, green 
and gold, respectively.  All points indicating noggin levels are solid, while all points 
indicating gremlin levels are shape outlines only. 
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Figure 15. Regression analysis of BMP expression vs. osteocyte density.  Data 
from proximal region represented with the symbol ♦ (diamond), mid shaft region 
represent with the symbol ● (circle), distal region represented with the symbol 
▲(triangle).  Cranial, caudal, medial and lateral points are color as blue, red, green 
and gold, respectively.  All points indicating noggin levels are solid, while all points 
indicating gremlin levels are shape outlines only. 
 
 
 
 
BMU Analysis 
 As one would expected of unloaded bone, our samples showed low 
levels of BMU activity.  Because of this, we were unable to confidently 
perform any statistical analysis by either region or quadrant.  Table 20 shows 
a summary of the number of BMUs positively identified. 
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Table 24.  Number of BMUs identified across all subjects by both region and 
quadrant. 
Region Quadrant BMUs present 
Proximal Cranial 0 
Proximal Caudal 1 
Proximal Medial 1 
Proximal Lateral 1 
Mid Shaft Cranial 1 
Mid Shaft Caudal 2 
Mid Shaft Medial 1 
Mid Shaft Lateral 0 
Distal Cranial 0 
Distal Caudal 0 
Distal Medial 0 
Distal Lateral 0 
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Discussion 
 
The primary objective of this study was to correlate the levels of the 
BMP antagonists noggin and gremlin with osteocyte and lacunar densities by 
region (proximal, mid shaft, and distal) and quadrant (cranial, caudal, medial, 
and lateral) in unloaded bone to determine if variations in any occur by 
location, as well as to determine any relationships that exists between BMP 
antagonist expression and osteocyte and lacunar densities.  We hypothesized 
that varying levels of BMP antagonist expression would coincide with 
variations in osteocyte density.  We also explored the possibility that BMP 
antagonist, osteocyte density, lacunar density, and the percentage of lacunae 
containing viable osteocyte vary by either anatomic region, quadrant, or both 
and expected to see some such variation.  These variations, especially if 
paired together, could point towards a response to varied signals from 
mechanical stimuli on osteocytes, and in turn the bone remodeling response 
to such stimuli.  We believe there will be a correlation because of the effect 
BMPs have on osteoblasts (increased activity) and by extension the 
osteoblastic activity in a BMU.  It would follow that with either increased or 
decreased BMP antagonist expression would factor, at least in part, to 
increased or decreased inhibition of osteoblastic activity, respectively.  
Conversely, if expression of the antagonists did not vary at all, we could infer 
that either osteocyte density does not affect BMP antagonist expression in 
bone or that some other mechanism or mechanisms are responsible for 
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remodeling initiation or continued function.  The hind tibia for mouse models 
were used because mice are relatively cheap and easily obtained and the 
hind limbs provide much more bone area than the forelimbs. 
Many theories put forward the idea that the osteocyte lacunar network 
plays a critical role in skeletal mechanotransduction.  In these hypotheses, 
osteocytes produce one or more signals that mediate skeletal modeling 
and/or remodeling, doing so in a dose-dependent manner. Gu et al. (2005) 
found in culture that osteocyte death stops the inhibition of osteoclasts, in turn 
triggering local bone resorption, supporting the theory that osteocytes can 
inhibit bone turnover processes in general.  Conversely, other studies have 
found greater osteocyte and lacunar densities in association with younger, 
more recently remodeled bone. Power et al. (2002) demonstrated greater 
levels of lacunae containing osteocytes and greater osteocyte density in bone 
surrounding forming and resorbing osteons compared with quiescent surfaces 
in human femoral necks.  
Other theories put forth the idea of targeted remodeling, supported by 
evidence of spatial differences in remodeling within a single bone responding 
to the uniform stimulus or environment change.  Bentolila, et al. (1998) 
observed spatial differences in bone matrix microdamage in uniformly fatigue-
loaded ulnar diaphysis of rats. Microdamage occurred principally in medial 
and lateral ulnar cortices. Furthermore, Bentolila, et al. reported that at 10 
days after loading, intracortical resorption was activated and resorption 
spaces were located principally in the medial and lateral cortices.  Emerton, et 
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al. (2009) performed ovariectomy on mice models and noted an 
approximately 2-fold increase in overall osteocyte apoptosis within the 
femoral cortex. This osteocyte apoptosis increase was not uniformly 
distributed throughout the diaphyseal cortex, but instead occurred 
overwhelmingly in the posterior cortical regions only.  The endocortical 
resorption following surgery occurred only on surfaces near the regions of 
elevated osteocyte apoptosis, again suggesting spatial remodeling 
differences.  Emerton, et al. concluded that following estrogen loss, osteocyte 
apoptosis occurs in cortical bone within a discrete and highly consistent area 
of the cortex that coincides with the region of subsequent increased bone 
resorption.  Noble, et al. (2003) demonstrated that under super-physiologic 
loads, osteocyte apoptosis is not systemic but highly localized to sites of 
microdamage that are subsequently remodeled.  In 2007, Hedgecock, et al. 
reported quandrantal and subregional differences in modeling and remodeling 
parameters, microcrack denities, as well as osteocyte apoptosis in rabbit tibia. 
Noble & Reeve (2000) stipulated that osteocytes direct the removal of 
damaged or redundant bone via mechanisms linked to their own apoptosis or 
the secretion of cellular attachment proteins although the extent of apoptosis 
or the pathway of signaling were undetermined.  More recent evidence 
suggests that viable osteocytes produce osteoblastic inhibatory molecules, of 
which BMP antagonists certainly fall into, as well as other pro-osteclastic 
factors (Noble, 2008). van Bezooijen, Papapoulos, et al. (2005) specifically 
showed the upregulation of sclerostin by osteocytes.  While scletostin is now 
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not considered a classic BMP antagonists it has shown BMP signal inhibition 
via non-classic BMP antagonist behavoior (van Bezooijen, Papapoulos, et al., 
2005).  Other research by van Bezooijen and coworkers show evidence that 
sclerostin production in bone is restriced to only osteocytes, with further 
evidence suggesting it as a negative regulator of bone formation in both 
mouse and human bone (van Bezooijen, ten Dijke, et al., 2005).  
BMPs have be described as key regulators of bone fracture healing, 
including initiation, healing speed and healing strength (Dean, et al., 2009).  
Concurrent research supports the claim by Dean, et al. Yu, et al. found 
evidence of both BMPs and BMP antagonists in isolated inflammatory cells 
associated with stabilized fracture healing (2009).  They also saw evidence of 
varying levels of noggin as fracture healing progressed.  Noggin was seen in 
activated periosteal cells 3 days post fracture but not 5 days post fracture, 
and noted the absence of noggin in endothelial cells associated with new 
bone in the callus phase of repair.  They concluded that the expression of 
BMP antagonists is closely associated with BMP and bone forming cells.    
Mitsui, et al. (2006) noted mechanical stimuli attributed with direct 
influence of bone remodeling are associated with changes in the homeostasis 
of hormones in the neighboring areas.  Specifically, excessive compressive 
forces on osteoblasts induce expression of extracellular antagonists of BMPs, 
inhibiting osteoblastogenesis. Perrien, et al. (2007) showed, in culture, that 
the addition of the noggin significantly decreased the number of mineralized 
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bone nodules in rats, demonstrating that baseline osteoblastogenesis in 
control medium was dependent on BMP production and function.   
BMPs and their antagonists are also believed to play a role in 
osteoclastogenesis and osteoclastic bone resorption.  Okamoto, et al. (2006) 
found increased bone volume associated with decreased bone formation rate 
and decreased osteoclast number in mice overexpressing noggin.  Wutzl, et 
al. (2006) demonstrated BMPs 5 and 6 influenced the generation of 
osteoclasts and that both proteins may be important regulators of bone 
homeostasis and are candidates for future treatment in bone regeneration.  
Mishina, et al. (2004) found that young, gene-mutated mice for BMP 
receptors showed irregular calcification and low bone mass but had normal 
numbers of osteoblasts. The study also found bone mass was increased in 
aged mutant mice due to reduced bone resorption associated with reduced 
bone turnover.  With all the research showing interplay between BMPs and 
BMP antagonists in a variety of bone repair and homeostasis, it would not be 
improbable to find variation in noggin or gremlin expression as the density of 
osteocytes change, resulting in changes in bone remodeling parameters.   
Our exploratory investigation into regional and quadrantal variation 
provided several interesting results.  Regional analysis between subjects 
showed the mid shaft having greater osteocyte densities than both the 
proximal and distal regions in addition to higher total lacunar density in the 
mid shaft as compared to the proximal region.  Interestingly, the mid shaft 
also had higher gremlin expression than both the proximal and distal regions, 
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indicating some relationship.  This did not seem to coincide with noggin 
expression, as antagonist levels showed a hierarchical trend with proximal 
levels higher than both distal and mid shaft, as well as the mid shaft showing 
marginally higher levels than the distal.  However, these seemingly 
confounding results were possibility explained when the regression analyses 
are looked at.  Regression analysis for gremlin showed moderate positive 
linear correlations between expression and osteocyte (R2= .5348, p= 0.007) 
and lacunar (R2= .3246, p= 0.053) densities which coincide with the regional 
ANOVA relationships found between these same variables.  Regression 
analysis for noggin showed a marginally significant negative linear correlation 
between expression and osteocyte density (R2= .2159, p= 0.13) explaining 
the results of the regional ANOVA relationships found for the same variable.   
Regional differences were also seen with respect to the percentage of 
lacunae containing viable osteocytes with the distal region showing lower 
percentages than both the proximal and mid shaft regions.  A significant 
positive correlation between gremlin expression and viability was seen (R2= 
.4961, p= 0.01), as was a marginally significant negative correlation between 
noggin expression and viability (R2= .2640, p=0.087). 
Quadrantal analysis showed no differences between any quadrants 
with respect to osteocyte density, total lacunar density, osteocyte viablilty nor 
gremlin expression and only a single difference in noggin expression (cranial 
quadrant showing higher levels than caudal).  These corresponding lacks of 
differences combined with the regional differences reported in osteocyte 
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density, lacunar density and antagonist expression confirm our hypothesis 
and point to relationships in the unloaded conditions. 
Other recent studies have shown that osteocyte apoptosis may have a 
controlling role in the activation of damage induced bone remodeling by 
indirect methods.  Cardoso, et al. (2009) showed that osteocyte apoptosis is 
necessary to initiate intracortical bone remodeling in response to fatigue 
microdamage in mature rat ulna, but by what exact mechanism remained 
unclear.  In response to this research, Schaffler, et al., (2010) suggests that 
viable osteocytes residing near microcracks are actively maintaining life near 
their apoptotic osteocyte neighbors and that these actively living osteocytes 
are responsible for the signaling of osteoclasts.  The question of how live, 
dead or both live and dead osteocytes factor into BMU initiation and function, 
as well as what multitude of signaling factors are involved is a controversial 
topic and one still under scrutiny. 
 
Limitations  
As previously mentioned, all subjects were housed in the University’s 
vivarium.  As such, we were unable to monitor the daily activity level of each 
individual subject to ensure similar activity levels.  We therefore assumed 
equal activity levels between subjects.  If this were not the case, varying 
activity could result in differing levels of mechanically induced bone 
remodeling and cytokine release or upkeep, affecting comparisons across 
subjects. 
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While viewing the staining for the immunohistochemical study under 
white light allowed us to quantify the BMP antagonists with a similar system 
previously used, other methods unavailable to us may have given additional 
information.  Noggin and gremlin presence may have been more readily 
detected if used with a Texas red filter system as described by Ermert et al. in 
(2001) where filtered light (central wavelength, 525 nm; half band width, 10 
nm ± 2 nm)  was used to observe the specific immunohistochemical substrate 
(VectaStain Red) used in our study. While we cannot know if such a light 
filtering system could have significantly changed any conclusions drawn here, 
it is impossible to say it would not.  Additionally, time and sample limitations 
could have affected the immunohistochemical staining as well as the methyl 
green counterstain.  Because of the amount of time each round of staining 
undertakes and the large amount of samples collected and analyzed, it is 
possible that daily variations in staining occurred.  In an attempt to control 
this, all staining was performed by only one researcher but it is possible such 
error could have occurred.  Furthermore, bone samples were not processed 
to include removal of surrounding muscle tissue.  This was done for two 
reasons: first and primarily, this study used subjects in conjunction with 
several other studies, some of which required the surrounding muscle tissue 
to remain; secondly and less importantly, while mice tibia are much larger 
than their associated forearms, they are still very small and would have been 
hard to indentify while embedded in paraffin, bringing up more possible 
complications during sectioning.  As such, the surrounding muscle tissue was 
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also stained, possibly altering the amount of chemicals each individual bone 
received. 
Finally, comparisons for regions (proximal, mid shaft, distal) were 
impossible to make for individual subjects.  When compared across subjects, 
all three regions were accounted for.  However, because of a number of 
factors, no single subject provided data for all three regions.  These factors 
included: individual occasions where the staining was unsuccessful, leaving 
“jumps” where bone tissue was unusable; bone sections becoming torn, 
ripped, folded or otherwise damaged during the sectioning and mounting 
stages (commonly occurred at the extremes of proximal and distal samples) 
and again becoming unusable; or “chunking” of samples occurring during 
sectioning.  The chunking mentioned occurred on more than one occasion if 
the microtome blade initially caught the wax embedded sample improperly or 
when the microtome was not in proper working function (occurred only once).   
This lack of complete regional data collection within subjects could also have 
an impact on analysis across subjects, as individual subject variation could 
potentially weigh into confirmation or discreditation of hypotheses. 
 
Future Research and Applications 
Bone morphogenetic proteins (BMP) are known to be key regulators of 
bone fracture healing including  initiation, healing speed and healing strength 
(Dean, et al., 2009).  Their role was originally identified in the 1960s by their 
ability to induce formation of new bone when implanted at ectopic 
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subcutaneous sites in rats (Dean, et al., 2009; Haudenschild, et al., 2004; 
Rosen, 2006).  This study looked at the possible interplay between BMP 
antagonists and their role in bone remodeling.  The idea of local BMP 
variation leading to a possible mechanism for remodeling of bone could be 
explained by either a local increase in the levels of BMPs or a local decrease 
in the levels of BMP antagonists.  We tried to investigate this by measuring 
the levels of two specific BMP antagonists and osteocyte and lacunar 
densities to see if they varied by bone location.  Additionally, since it has been 
shown that antagonists are products of osteoblasts and are produced as 
osteoblastic BMPs rise, we also attempted to find a correlation between BMP 
antagonists and viable osteocytes in varying areas of bone (Gazzerro, et al., 
2005; Rosen, 2006).  Combined with the relationships found here, data on 
bone under controlled loading conditions could further expand our 
understanding of bone remodeling, cell fates and cellular cytokine expression. 
Manipulation of BMP and BMP antagonists is still a possible avenue 
for medical and biologic research and therapy.  Research studies have shown 
that BMPs have some therapeutic effects in both joint disorder and fracture 
healing (Dean, et al., 2009; Lories, et al., 2005).  Whether such therapies are 
viable or the most effective method of treatment is still yet to be determined.  
It was the hope that this study could be a step towards further understanding 
of bone health and remodeling.  Our results show some evidence of regional 
variations and coinciding lacks of quadrantal variations leaving open the 
possibility that, combined with research under different physiologic conditions, 
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these ideas could be taken further.  Specfically, comparisons where bone 
remodeling was induced could show different or stronger variations in 
antagonist expression and osteocyte densities in response to bone 
adaptation.   
Future research could also include other species.  Hedgecock, et al. 
reported regional differences in bone modeling, remodeling and osteocyte 
apoptosis in rabbit tibia (2007).  By scaling up the size of subject (as 
compared to mice), they were able to see more evidence of bone remodeling.  
Further animal testing such as that could eventually lead to human test 
samples if results were shown to be positive. 
We also compared only osteocytes stained as viable in this study, 
exploring only the possibility that viable osteocytes would be responsible for 
variations in BMP antagonist levels.  It is possible that BMP antagonist levels 
vary in the presence of recently apoptotic osteocytes as well.  Cell death 
could induce large amounts of BMP antagonist release upon death changing 
levels in the surrounding tissue.  It is also possible cell death could result in 
cessation of specific protein production as the cell dies, again resulting in 
changing levels in the surrounding tissue.  Additional studies looking into the 
regional and quadrantal differences in apoptosis could help support claims 
here and further our understanding. 
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Conclusion 
 The results of this study show that immunohistochemical processes 
are a viable way to determine the presence of cytokines in murine bone 
samples.  Because of this, we were able to establish baselines for noggin and 
gremlin expression in unloaded bone as well as describe their possible 
relationships with osteocyte density in cortical bone.  Further research with 
super-physiologic loading conditions, resulting in altered cell activity as bone 
adapts to mechanical environment changes, would provide us with more 
information on the interplay of osteocytes, BMP antagonist expression and 
bone remodeling.   
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Appendix A 
 
P values for the differences in Osteocyte Density with respect to the 
interaction of regions and quadrants 
Response Variable OD 
All Pairwise Comparisons among Levels of quadrant*region 
quadrant = caudal 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
caudal    midshaft      136.14       86.54   1.5731    0.8991 
caudal    proximal      -45.07       77.40  -0.5822    1.0000 
cranial   distal          8.60       77.40   0.1111    1.0000 
cranial   midshaft      189.48       86.54   2.1894    0.5742 
cranial   proximal       68.91       86.54   0.7962    0.9994 
lateral   distal         28.46       77.40   0.3676    1.0000 
lateral   midshaft      119.41       86.54   1.3798    0.9541 
lateral   proximal      128.03       77.40   1.6541    0.8677 
medial    distal         24.02       77.40   0.3103    1.0000 
medial    midshaft      171.70       86.54   1.9840    0.6981 
medial    proximal      -47.04       77.40  -0.6077    1.0000 
 
 
quadrant = caudal 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
caudal    proximal      -181.2       86.54   -2.094    0.6324 
cranial   distal        -127.5       86.54   -1.474    0.9308 
cranial   midshaft        53.3       94.80    0.563    1.0000 
cranial   proximal       -67.2       94.80   -0.709    0.9998 
lateral   distal        -107.7       86.54   -1.244    0.9772 
lateral   midshaft       -16.7       94.80   -0.176    1.0000 
lateral   proximal        -8.1       86.54   -0.094    1.0000 
medial    distal        -112.1       86.54   -1.296    0.9698 
medial    midshaft        35.6       94.80    0.375    1.0000 
medial    proximal      -183.2       86.54   -2.117    0.6185 
 
 
quadrant = caudal 
region = proximal  subtracted from: 
 
                    Difference       SE of            Adjusted 
quadrant  region      of Means  Difference   T-Value   P-Value 
cranial   distal        53.669       77.40   0.69336    0.9998 
cranial   midshaft     234.543       86.54   2.71019    0.2917 
cranial   proximal     113.975       86.54   1.31700    0.9663 
lateral   distal        73.522       77.40   0.94984    0.9972 
lateral   midshaft     164.473       86.54   1.90051    0.7460 
lateral   proximal     173.100       77.40   2.23630    0.5458 
medial    distal        69.088       77.40   0.89255    0.9984 
medial    midshaft     216.764       86.54   2.50475    0.3919 
medial    proximal      -1.971       77.40  -0.02547    1.0000 
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quadrant = cranial 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
cranial   midshaft      180.87       86.54   2.0900    0.6347 
cranial   proximal       60.31       86.54   0.6968    0.9998 
lateral   distal         19.85       77.40   0.2565    1.0000 
lateral   midshaft      110.80       86.54   1.2804    0.9722 
lateral   proximal      119.43       77.40   1.5429    0.9095 
medial    distal         15.42       77.40   0.1992    1.0000 
medial    midshaft      163.09       86.54   1.8846    0.7549 
medial    proximal      -55.64       77.40  -0.7188    0.9998 
 
 
quadrant = cranial 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
cranial   proximal      -120.6       94.80   -1.272    0.9734 
lateral   distal        -161.0       86.54   -1.861    0.7680 
lateral   midshaft       -70.1       94.80   -0.739    0.9997 
lateral   proximal       -61.4       86.54   -0.710    0.9998 
medial    distal        -165.5       86.54   -1.912    0.7397 
medial    midshaft       -17.8       94.80   -0.188    1.0000 
medial    proximal      -236.5       86.54   -2.733    0.2817 
 
 
quadrant = cranial 
region = proximal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
lateral   distal         -40.5       86.54   -0.467    1.0000 
lateral   midshaft        50.5       94.80    0.533    1.0000 
lateral   proximal        59.1       86.54    0.683    0.9999 
medial    distal         -44.9       86.54   -0.519    1.0000 
medial    midshaft       102.8       94.80    1.084    0.9919 
medial    proximal      -115.9       86.54   -1.340    0.9622 
 
 
quadrant = lateral 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
lateral   midshaft       90.95       86.54   1.0510    0.9936 
lateral   proximal       99.58       77.40   1.2865    0.9713 
medial    distal         -4.43       77.40  -0.0573    1.0000 
medial    midshaft      143.24       86.54   1.6552    0.8673 
medial    proximal      -75.49       77.40  -0.9753    0.9965 
 
 
quadrant = lateral 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
lateral   proximal         8.6       86.54    0.100    1.0000 
medial    distal         -95.4       86.54   -1.102    0.9908 
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medial    midshaft        52.3       94.80    0.552    1.0000 
medial    proximal      -166.4       86.54   -1.923    0.7332 
 
 
quadrant = lateral 
region = proximal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
medial    distal        -104.0       77.40   -1.344    0.9614 
medial    midshaft        43.7       86.54    0.505    1.0000 
medial    proximal      -175.1       77.40   -2.262    0.5304 
 
 
quadrant = medial 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
medial    midshaft      147.68       86.54   1.7064    0.8450 
medial    proximal      -71.06       77.40  -0.9180    0.9979 
 
 
quadrant = medial 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
medial    proximal      -218.7       86.54   -2.528    0.3799 
 
 
 
P values for the differences in Total Lacunar Density with respect to the 
interaction of regions and quadrants 
Response Variable TLD 
All Pairwise Comparisons among Levels of quadrant*region 
quadrant = caudal 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
caudal    midshaft      158.81       113.8   1.3953    0.9507 
caudal    proximal       14.48       101.8   0.1422    1.0000 
cranial   distal         76.84       101.8   0.7548    0.9996 
cranial   midshaft      186.50       113.8   1.6385    0.8741 
cranial   proximal       42.17       113.8   0.3705    1.0000 
lateral   distal         53.16       101.8   0.5222    1.0000 
lateral   midshaft      125.05       113.8   1.0987    0.9910 
lateral   proximal      198.65       101.8   1.9513    0.7171 
medial    distal         59.34       101.8   0.5829    1.0000 
medial    midshaft      166.76       113.8   1.4652    0.9332 
medial    proximal      -69.01       101.8  -0.6779    0.9999 
 
 
quadrant = caudal 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
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quadrant  region      of Means  Difference  T-Value   P-Value 
caudal    proximal      -144.3       113.8   -1.268    0.9740 
cranial   distal         -82.0       113.8   -0.720    0.9998 
cranial   midshaft        27.7       124.7    0.222    1.0000 
cranial   proximal      -116.6       124.7   -0.935    0.9976 
lateral   distal        -105.6       113.8   -0.928    0.9977 
lateral   midshaft       -33.8       124.7   -0.271    1.0000 
lateral   proximal        39.8       113.8    0.350    1.0000 
medial    distal         -99.5       113.8   -0.874    0.9987 
medial    midshaft         8.0       124.7    0.064    1.0000 
medial    proximal      -227.8       113.8   -2.002    0.6878 
 
 
quadrant = caudal 
region = proximal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
cranial   distal         62.36       101.8   0.6126    1.0000 
cranial   midshaft      172.02       113.8   1.5113    0.9197 
cranial   proximal       27.69       113.8   0.2433    1.0000 
lateral   distal         38.68       101.8   0.3800    1.0000 
lateral   midshaft      110.57       113.8   0.9714    0.9967 
lateral   proximal      184.17       101.8   1.8091    0.7952 
medial    distal         44.86       101.8   0.4406    1.0000 
medial    midshaft      152.28       113.8   1.3379    0.9625 
medial    proximal      -83.49       101.8  -0.8201    0.9992 
 
 
quadrant = cranial 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
cranial   midshaft       109.7       113.8    0.963    0.9969 
cranial   proximal       -34.7       113.8   -0.305    1.0000 
lateral   distal         -23.7       101.8   -0.233    1.0000 
lateral   midshaft        48.2       113.8    0.424    1.0000 
lateral   proximal       121.8       101.8    1.197    0.9828 
medial    distal         -17.5       101.8   -0.172    1.0000 
medial    midshaft        89.9       113.8    0.790    0.9995 
medial    proximal      -145.9       101.8   -1.433    0.9418 
 
 
quadrant = cranial 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
cranial   proximal      -144.3       124.7   -1.158    0.9866 
lateral   distal        -133.3       113.8   -1.171    0.9853 
lateral   midshaft       -61.4       124.7   -0.493    1.0000 
lateral   proximal        12.2       113.8    0.107    1.0000 
medial    distal        -127.2       113.8   -1.117    0.9897 
medial    midshaft       -19.7       124.7   -0.158    1.0000 
medial    proximal      -255.5       113.8   -2.245    0.5406 
 
 
quadrant = cranial 
region = proximal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
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lateral   distal          11.0       113.8   0.0966    1.0000 
lateral   midshaft        82.9       124.7   0.6647    0.9999 
lateral   proximal       156.5       113.8   1.3748    0.9552 
medial    distal          17.2       113.8   0.1508    1.0000 
medial    midshaft       124.6       124.7   0.9993    0.9958 
medial    proximal      -111.2       113.8  -0.9768    0.9965 
 
 
quadrant = lateral 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
lateral   midshaft        71.9       113.8    0.632    0.9999 
lateral   proximal       145.5       101.8    1.429    0.9427 
medial    distal           6.2       101.8    0.061    1.0000 
medial    midshaft       113.6       113.8    0.998    0.9958 
medial    proximal      -122.2       101.8   -1.200    0.9824 
 
 
quadrant = lateral 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
lateral   proximal        73.6       113.8    0.647    0.9999 
medial    distal         -65.7       113.8   -0.577    1.0000 
medial    midshaft        41.7       124.7    0.335    1.0000 
medial    proximal      -194.1       113.8   -1.705    0.8456 
 
 
quadrant = lateral 
region = proximal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
medial    distal        -139.3       101.8   -1.368    0.9565 
medial    midshaft       -31.9       113.8   -0.280    1.0000 
medial    proximal      -267.7       101.8   -2.629    0.3290 
 
 
quadrant = medial 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
medial    midshaft       107.4       113.8    0.944    0.9974 
medial    proximal      -128.3       101.8   -1.261    0.9750 
 
 
quadrant = medial 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
medial    proximal      -235.8       113.8   -2.071    0.6459 
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P values for the differences in the percentage of lacunae containing viable 
osteocytes with respect to the interaction of regions and quadrants 
Response Variable % viable osteocytes 
All Pairwise Comparisons among Levels of quadrant*region 
quadrant = caudal 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
caudal    midshaft     0.01812     0.05035    0.360    1.0000 
caudal    proximal    -0.05932     0.04504   -1.317    0.9663 
cranial   distal      -0.05312     0.04504   -1.179    0.9845 
cranial   midshaft     0.05002     0.05035    0.993    0.9960 
cranial   proximal     0.04608     0.05035    0.915    0.9980 
lateral   distal      -0.00215     0.04504   -0.048    1.0000 
lateral   midshaft     0.02837     0.05035    0.563    1.0000 
lateral   proximal    -0.01893     0.04504   -0.420    1.0000 
medial    distal      -0.02296     0.04504   -0.510    1.0000 
medial    midshaft     0.04411     0.05035    0.876    0.9986 
medial    proximal     0.00749     0.04504    0.166    1.0000 
 
 
quadrant = caudal 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
caudal    proximal    -0.07744     0.05035   -1.538    0.9112 
cranial   distal      -0.07124     0.05035   -1.415    0.9462 
cranial   midshaft     0.03190     0.05516    0.578    1.0000 
cranial   proximal     0.02797     0.05516    0.507    1.0000 
lateral   distal      -0.02026     0.05035   -0.402    1.0000 
lateral   midshaft     0.01025     0.05516    0.186    1.0000 
lateral   proximal    -0.03704     0.05035   -0.736    0.9997 
medial    distal      -0.04107     0.05035   -0.816    0.9993 
medial    midshaft     0.02599     0.05516    0.471    1.0000 
medial    proximal    -0.01062     0.05035   -0.211    1.0000 
 
 
quadrant = caudal 
region = proximal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
cranial   distal      0.006199     0.04504   0.1376    1.0000 
cranial   midshaft    0.109341     0.05035   2.1714    0.5852 
cranial   proximal    0.105405     0.05035   2.0932    0.6327 
lateral   distal      0.057174     0.04504   1.2694    0.9738 
lateral   midshaft    0.087691     0.05035   1.7415    0.8287 
lateral   proximal    0.040392     0.04504   0.8968    0.9983 
medial    distal      0.036362     0.04504   0.8073    0.9993 
medial    midshaft    0.103430     0.05035   2.0540    0.6564 
medial    proximal    0.066815     0.04504   1.4835    0.9280 
 
 
quadrant = cranial 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
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quadrant  region      of Means  Difference  T-Value   P-Value 
cranial   midshaft     0.10314     0.05035   2.0483    0.6599 
cranial   proximal     0.09921     0.05035   1.9701    0.7062 
lateral   distal       0.05097     0.04504   1.1318    0.9887 
lateral   midshaft     0.08149     0.05035   1.6184    0.8821 
lateral   proximal     0.03419     0.04504   0.7592    0.9996 
medial    distal       0.03016     0.04504   0.6697    0.9999 
medial    midshaft     0.09723     0.05035   1.9309    0.7289 
medial    proximal     0.06062     0.04504   1.3459    0.9610 
 
 
quadrant = cranial 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
cranial   proximal    -0.00394     0.05516   -0.071    1.0000 
lateral   distal      -0.05217     0.05035   -1.036    0.9943 
lateral   midshaft    -0.02165     0.05516   -0.392    1.0000 
lateral   proximal    -0.06895     0.05035   -1.369    0.9564 
medial    distal      -0.07298     0.05035   -1.449    0.9375 
medial    midshaft    -0.00591     0.05516   -0.107    1.0000 
medial    proximal    -0.04253     0.05035   -0.845    0.9990 
 
 
quadrant = cranial 
region = proximal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
lateral   distal      -0.04823     0.05035   -0.958    0.9970 
lateral   midshaft    -0.01771     0.05516   -0.321    1.0000 
lateral   proximal    -0.06501     0.05035   -1.291    0.9705 
medial    distal      -0.06904     0.05035   -1.371    0.9560 
medial    midshaft    -0.00197     0.05516   -0.036    1.0000 
medial    proximal    -0.03859     0.05035   -0.766    0.9996 
 
 
quadrant = lateral 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
lateral   midshaft     0.03052     0.05035   0.6060    1.0000 
lateral   proximal    -0.01678     0.04504  -0.3726    1.0000 
medial    distal      -0.02081     0.04504  -0.4621    1.0000 
medial    midshaft     0.04626     0.05035   0.9186    0.9979 
medial    proximal     0.00964     0.04504   0.2141    1.0000 
 
 
quadrant = lateral 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
lateral   proximal    -0.04730     0.05035   -0.939    0.9975 
medial    distal      -0.05133     0.05035   -1.019    0.9950 
medial    midshaft     0.01574     0.05516    0.285    1.0000 
medial    proximal    -0.02088     0.05035   -0.415    1.0000 
 
 
quadrant = lateral 
region = proximal  subtracted from: 
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                    Difference       SE of            Adjusted 
quadrant  region      of Means  Difference   T-Value   P-Value 
medial    distal     -0.004030     0.04504  -0.08948    1.0000 
medial    midshaft    0.063038     0.05035   1.25188    0.9762 
medial    proximal    0.026423     0.04504   0.58667    1.0000 
 
 
quadrant = medial 
region = distal  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
medial    midshaft     0.06707     0.05035   1.3319    0.9636 
medial    proximal     0.03045     0.04504   0.6762    0.9999 
 
 
quadrant = medial 
region = midshaft  subtracted from: 
 
                    Difference       SE of           Adjusted 
quadrant  region      of Means  Difference  T-Value   P-Value 
medial    proximal    -0.03662     0.05035  -0.7271    0.9997 
